No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility

  title={No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility},
  author={Peter Doshi},
  journal={BMJ : British Medical Journal},
  • P. Doshi
  • Published 2015
  • Medicine
  • BMJ : British Medical Journal
As a new data analysis adds weight to calls for retraction of a paper on paroxetine in adolescents, Peter Doshi examines the resistance to action of a professional society, its journal, and an Ivy League university 

Topics from this paper

Restoring Study 329: Paroxetine neither effective nor safe for adolescents
A major reanalysis of Study 329, a Glaxo Smith Kline (GSK) randomised controlled trial (RCT) comparing paroxetine, imipramine and placebo published in the British Medical Journal (BMJ), has concludedExpand
Study 329 and the use of paroxetine in child and adolescent unipolar depression
The authors demonstrated that the antidepressant is neither safe nor effective in adolescent depression, and highlighted the need of making primary trial data and protocols available to increase the thoroughness of the evidence. Expand
The Ethical Judgment: Chemical Psychotropics
In the case of psychotropic and nootropic substances, evidence is abundant that the pharmaceutical industries are violating elementary ethical norms, implying a serious liability not only for companyExpand
2015: a year in review
  • S. Arie
  • Medicine
  • BMJ : British Medical Journal
  • 2015
Sophie Arie looks back at some of the journal’s most important and widely read articles of 2015. Expand
Just Evidence: Opening Health Knowledge to a Parliament of Evidence
This is the Accepted Manuscript of a published book chapter. The publisher's version appears in "Science, Information, and Policy Interface for Effective Coastal and Ocean Management", Chapter 14.Expand
Liberating the data from clinical trials
Liberated trial data have enduring potential to benefit patients, prevent harm, and correct misleading research
Benefits, harms and evidence – reflections from UK primary healthcare
  • M. McCartney
  • Psychology, Medicine
  • London journal of primary care
  • 2018
It is concluded that even perfect knowledge about benefits and harms requires to be translated in the context of the individual patient: it also requires to been interpreted according to what that persons’ wishes are. Expand
The Effect of Financial Conflict of Interest, Disclosure Status, and Relevance on Medical Research from the United States
All financial COIs (disclosed or undisclosed, relevant or not relevant, research or non-research) influence whether studies report findings favorable to industry sponsors. Expand
The Sunshine Act: Moving Forward.
The concern is that relying on disclosure alone to manage financial conflicts will produce the same results that it has on Wall Street, namely sustaining the status quo and a loss of public confidence in oversight. Expand
MedEdTrials: Protocol registration for medical education research [Version 2]
• Reviewer 1 [FS]: No changes required. • Reviewer 2 [BA]: (1) How to register and whom to register? A parenthetical explanation has now been added to the first bullet point under the MedEdTrialsExpand


Restoring invisible and abandoned trials: a call for people to publish the findings
Peter Doshi and colleagues call for sponsors and investigators of abandoned studies to publish (or republish) and propose a system for independent publishing if sponsors fail to respond. Expand
Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence
The reanalysis of Study 329 illustrates the necessity of making primary trial data and protocols available to increase the rigour of the evidence base and access to primary data from trials has important implications for both clinical practice and research. Expand
Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial.
Paroxetine demonstrated significantly greater improvement compared with placebo in Hamilton Rating Scale for Depression total score < or = 8, HAM-D depressed mood item, K-SADS-L depressed Mood item, and CGI score of 1 or 2. Expand